Miskolc, Hungary Clinical Trials

A listing of Miskolc, Hungary clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 73 clinical trials
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.

hemoglobin a1c
fasting
c-peptide
metformin
body mass index
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi OktatoKorhaz ( Site 0701)
 (1.4 away) Contact site
  • 271 views
  • 28 Jul, 2021
  • +105 other locations
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynamics of the tumor microenvironment changes on treatment by comparing pre-, on- and post-treatment …

pembrolizumab
Novartis Investigative Site
 (1.4 away) Contact site
  • 7 views
  • 02 Jun, 2021
  • +43 other locations
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

diabetes
stroke
infarct
arterial disease
myocardial infarction
Research Site
 (0.8 away) Contact site
  • 536 views
  • 04 Jul, 2021
  • +1332 other locations
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis

This Phase IIa study aims at investigating the safety and tolerability of 2 dose-levels of ABX464 administered daily in combination with methotrexate (MTX) in patients with moderate to severe active Rheumatoid Arthritis (RA) who had an inadequate response to MTX or/and to one or more anti- tumor necrosis factor alpha …

tumor necrosis factor
erosion
tumor necrosis factor alpha
rheumatism
methotrexate
Complex Medical Centre - D li Klinika
 (90.5 away) Contact site
  • 3 views
  • 27 Jan, 2021
  • +34 other locations
Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric subjects with episodic migraine, the combined erenumab dose group has a greater reduction from baseline …

erenumab
episodic migraine
headache
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz
 (0.8 away) Contact site
  • 226 views
  • 28 Jul, 2021
  • +177 other locations
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage …

c-MET
cancer chemotherapy
epidermal growth factor
lung carcinoma
stage iv non-small cell lung cancer
CRU Hungary Egeszsegugyi s Szolgaltato Kft. /ID# 204878
 (0.8 away) Contact site
  • 118 views
  • 28 Jul, 2021
  • +363 other locations
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC).

mirikizumab
Endomedix Diagnosztikai Kozpont
 (1.1 away) Contact site
  • 257 views
  • 21 Jul, 2021
  • +611 other locations
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

mirikizumab
Endomedix Diagnosztikai Kozpont
 (1.1 away) Contact site
  • 1722 views
  • 24 Jul, 2021
  • +880 other locations
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or IIA non-small cell lung cancer (NSCLC). The primary study hypotheses are: SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared …

mk-3475
pembrolizumab
stereotactic body radiation therapy
lung carcinoma
CRU Hungary KFT ( Site 2309)
 (0.8 away) Contact site
  • 121 views
  • 28 Jul, 2021
  • +178 other locations
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

The purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) 10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with …

solid tumour
hearing loss
neuropathy
bladder cancer
platinum-based chemotherapy
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0506)
 (1.4 away) Contact site
  • 69 views
  • 28 Jul, 2021
  • +228 other locations